$28.850
-0.433 (-1.50%)收盘时
- High
- 30.550
- Open
- 29.380
- VWAP
- 29.33
- Vol
- 205.15K
- Mkt Cap
- 7.30M
- Low
- 28.600
- Amount
- 6.02M
- EV/EBITDA, TTM
- -58.66
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
AI analysis of Precipio Inc (PRPO)
buyPrecipio Inc is a good buy right now due to its recent revenue growth and improving financial metrics. The stock is currently priced at $28.85, and it has shown a significant year-over-year revenue increase of 29.8% with Q2 2026 revenue exceeding $7 million. Additionally, the gross margin has improved to 75.4%, which is a strong indicator of operational efficiency. However, the main risk is the net income loss of $1.44 million in Q1 2026, which highlights ongoing challenges in achieving profitability.
Analyst Ratings (1)
估值指标
事件时间线
资讯
9.508-21Yahoo FinancePrecipio Reports Over $7 Million Revenue in Q2 2026
9.006-12NewsfilterPrecipio Urges Shareholders to Vote for Quorum at Annual Meeting
- 1.006-11Newsfilter
Precipio to Present at Planet MicroCap Las Vegas 2026
9.505-14seekingalphaPrecipio Reports Q1 Financial Results with Revenue Growth
- 5.005-13Newsfilter
Precipio Management Stock Options Vesting Announcement
PRPO FAQ — answered by Alphio AI
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Precipio Inc is a good buy right now due to its recent revenue growth and improving financial metrics. The stock is currently priced at $28.85, and it has shown a significant year-over-year revenue increase of 29.8% with Q2 2026 revenue exceeding $7 million. Additionally, the gross margin has improved to 75.4%, which is a strong indicator of operational efficiency. However, the main risk is the net income loss of $1.44 million in Q1 2026, which highlights ongoing challenges in achieving profitability.
1 analysts cover PRPO: 1 rate it Buy, 0 Hold and 0 Sell.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。